Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This is an interventional, single arm, open-label, feasibility trial with gemcitabine and
nab-paclitaxel, followed by concomitant proton therapy and capecitabine, followed by
re-evaluation and surgery (when feasible) for patients with borderline resectable pancreatic
cancer.